New Endpoints, Programs Used for Drug Approvals.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-010
Abstract: The FDA greenlighted 17 novel cancer agents in 2018, including one with a novel endpoint in a clinical trial and one through an expanded access program. The agency also approved five biosimilars to treat cancer… read more here.
Keywords: drug approvals; cancer; new endpoints; programs used ... See more keywords